
Foretell My Health is a Korean biotechnology company specializing in early cancer detection through innovative liquid biopsy services. Their key product, Magnolia, utilizes platelet-derived RNA analysis combined with AI-based cancer discrimination algorithms to simultaneously screen for ovarian and endometrial cancers at early stages. This technology overcomes the limitations of traditional imaging diagnostics and tissue biopsies by analyzing RNA biomarkers in platelets, enabling accurate and non-invasive early cancer detection from a single blood draw. The company emphasizes innovation, safety, and effectiveness in its diagnostic solutions, aiming to maintain individuals' health by foretelling health risks early. Foretell My Health operates with a strong leadership team of Ph.D. experts and medical professionals, and it is based in Pohang, South Korea. Their business model is primarily service-based, offering liquid biopsy diagnostic services to healthcare providers and patients.

Foretell My Health is a Korean biotechnology company specializing in early cancer detection through innovative liquid biopsy services. Their key product, Magnolia, utilizes platelet-derived RNA analysis combined with AI-based cancer discrimination algorithms to simultaneously screen for ovarian and endometrial cancers at early stages. This technology overcomes the limitations of traditional imaging diagnostics and tissue biopsies by analyzing RNA biomarkers in platelets, enabling accurate and non-invasive early cancer detection from a single blood draw. The company emphasizes innovation, safety, and effectiveness in its diagnostic solutions, aiming to maintain individuals' health by foretelling health risks early. Foretell My Health operates with a strong leadership team of Ph.D. experts and medical professionals, and it is based in Pohang, South Korea. Their business model is primarily service-based, offering liquid biopsy diagnostic services to healthcare providers and patients.